BCM
NMRA icon

Brookstone Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Brookstone Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,201
Closed -$42.2K – 1211
2025
Q3 		$42.2K Buy
+23,201
New +$37.5K ﹤0.01% 1128

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Brookstone Capital Management's NMRA Position: Q4 2025 in Review

Brookstone Capital Management sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 23,201 shares — an estimated $42.2K sold.

Brookstone Capital Management first reported a position in NMRA in Q3 2025 and held it in 1 quarter. The position peaked at $42.2K in Q3 2025. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • Brookstone Capital Management reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brookstone Capital Management sold 23,201 Neumora Therapeutics shares in Q4 2025, an estimated $42.2K.
  • Brookstone Capital Management first reported a position in Neumora Therapeutics in Q3 2025 and held it in 1 quarter.
  • Brookstone Capital Management's Neumora Therapeutics position peaked at $42.2K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on Brookstone Capital Management's 13F filing for Q4 2025, filed 15 Jan 2026.